Phathom Pharmaceuticals presents Phase 2 results showing VOQUEZNA® effectively relieves heartburn for Non-Erosive GERD in 3 hours, with lasting effects and potential for As Needed dosing.
Phathom Pharmaceuticals will present findings on its treatment VOQUEZNA® (vonoprazan) for Non-Erosive Gastroesophageal Reflux Disease (GERD) at the ACG 2024 Annual Meeting. A Phase 2 study showed that all tested doses effectively relieved heartburn within three hours, with effects lasting 24 hours. The study highlights the potential of As Needed dosing as an alternative for heartburn relief. Additionally, a poster will address nocturnal GERD symptoms in patients.
October 27, 2024
5 Articles